Skip to main content

Table 1 Characteristics and prevalence of comorbid conditions in African American males and females

From: Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females

Variable

Men (n = 402)

Women (n = 1004)

NTN (n = 92)

HTN (n = 301)

HTN + Spiro (n = 9)

NTN (n = 172)

HTN (n = 823)

HTN + Spiro (n = 9)

Age (year)

58 ± 9

65 ± 9*

63 ± 9

56 ± 10

64 ± 9*

68 ± 9*

BMI (kg/m2)

28 ± 5

29 ± 5*

34 ± 6*#

31 ± 7+

33 ± 7*+

33 ± 4

HTN medications

0

1.7 ± 1.1*

2.7 ± 1.3*#

0

1.7 ± 1.1*

1.8 ± 0.8*

HTN duration (year)

0

15 ± 12*

15 ± 11*

0

17 ± 13*

29 ± 11*#+

eGFR (ml/min)

104 ± 17

87 ± 24*

93 ± 14*

96 ± 10+

87 ± 14*

79 ± 16*

LV mass (g/m2)

75 ± 14

90 ± 22*

90 ± 7*

68 ± 12+

80 ± 18*+

73 ± 10+

Total urinary protein (mg)

4 ± 7

16 ± 44*

11 ± 10*

4 ± 6

12 ± 34*

3 ± 3#+

Uncontrolled HTN (%)

0

48*

44*

0

46*

0#+

CHD (%)

2

17*

22*

1

9*+

11*

MI (%)

0

10*

22*

1

4*+

11*

Stroke (%)

1

10*

22*

1

5*+

0

Diabetes (%)

10

30*

11

8

31*

33*

  1. NTN indicates normotension, HTN hypertension, HTN + Spiro hypertension with spironolactone treatment, BMI body mass index, HTN hypertension, eGFR estimate glomerular filtration rate, LV left ventricle, CHD coronary heart disease, MI myocardial infarction. *p < 0.05 vs. NTN, #p < 0.05 vs. HTN, +p < 0.05 vs. men